
 |
|
May 25, 2012
Mark Clayton: Is Hillary's State Dept. hacking Al Qaeda? Not quite
Erika Bolstad: Temple cancels Wasserman Schultz speech
The Kosher Gourmet by Ethel G. Hofman: The former president of the International Association of Culinary Professionals, whose members included the likes of Julia Child, is back with contemporary Shavous cuisine: Ruby Fruit Soup, Sweet Noodle Kugel with Cheese, Key Lime Curd, Calsone Casserole Frittata with Wild Mushrooms, Sun-dried tomatoes and Olives, Baked Tilapia with Pepper Cheese Cream and Brown Sugar Shortbread
May 24, 2012
Jeff Jacoby: The peace process battered Israel's reputation
Michael Muskal: 'Pro-choice' position hits record low, according to poll
Chris Farrell: Are We in a Tech Bubble?
The Kosher Gourmet by Penelope Wall: PHILLY CHEESE STEAKS --- hold the steak!
May 23, 2012
Tony Pugh: More private colleges offering tuition discounts
Mary Beth Franklin: How to Choose the Right Annuity for You
Tina Susman: The wig wasn't enough: Man gets 13 years for posing as his dead mom
The Kosher Gourmet by Emma Christensen:A simple way to do fish right
May 22, 2012
Warren Richey: Can US group challenge overseas surveillance act? Supreme Court to decide
Thomas M. Anderson: Walking Away From a Mortgage
The Kosher Gourmet by Megan Gordon: Enjoy a celebration of the most rich and layered flavors: Black bean, sweet potato and quinoa chili
May 21, 2012
Mark Clayton: Cybersecurity: How US utilities passed up chance to protect their networks
Howard LaFranchi: NATO summit: Who will foot the bill for long-term Afghanistan security?
Chris Farrell : Earn Dividends in Emerging Markets with This WisdomTree ETF
Stephen Whiteside, Ph.D. : Mayo Clinic Medical Edge: Social anxiety disorder --- or just shy?
Guy Jackson : Victim's father regrets death of Lockerbie bomber
The Kosher Gourmet by Mario Batali: Famed chef's veal shoulder farsumagru: A festive meat course for late spring
May 18, 2012
Rabbi Berel Wein: Striving: The People of the Book's Book for (All of) the People
Steven Goldberg: 5 Great Stock Picks and the Exchange-Traded Fund that Owns Them
Mary Pickett, M.D.: Ask the Harvard Experts: Don't be forced into gluten-free lifestyle based merely on a doctor's false-positive test
The Kosher Gourmet by Carolyn Malcoun: DIY healthy lunchbox treats: HOMEMADE FRUIT BARS for kids and brown-bagging adults alike
May 17, 2012
Warren Richey: Teacher fired for being unwed and pregnant can sue religious school, court rules
Josh Mitnick: Netanyahu's 'centrist' coalition is already proving it's anything but
Steven Goldberg: Earn Dividends in Emerging Markets with This WisdomTree ETF
Amina Khan: Research links coffee to lower death rates
The Kosher Gourmet by Faith Duran : Cheesy Potato Breakfast Casserole with Cheddar and Sun-Dried Tomatoes
May 16, 2012
Carmen Terzic, M.D., Ph.D. : Mayo Clinic Medical Edge: A variety of exercises can help improve balance
Melissa Healy: National strategy on Alzheimer's disease aims to halt it by 2025
The Kosher Gourmet by Joyce White : GOODNESS GRACIOUS: GREENS! 4 winning recipes that are no longer just for down-home folks (Includes expert tips & techniques)
May 15, 2012
Kristen Chick: Obama administration resumes arms sales to Bahrain despite serious unresolved human rights issues. Activists feel abandoned
Pat Mertz Esswein: Homes are now affordable again and mortgage rates are low. What you need to know before you buy
Kathy Kristof: Our Practical Investor Fights Inflation with These 6 Investments
Sue Hubbard, M.D.: The Kid's Doctor: Lactose intolerant young child? Check again
The Kosher Gourmet by Kathy Hunt: Spread a Little Excitement with EXOTIC CONDIMENTS (4 RECIPES)
May 14, 2012
Lisa Gerstner: How to Protect Your Identity, Finances If You Lose Your Phone
Harvard Health Letters: Heart disease and dementia
The Kosher Gourmet by Megan Gordon: MANGO COCONUT OAT MORNING MUFFINS are a bright but hearty delight
May 11, 2012
Jessica L. Anderson: Get the Best Deal on a Used Car
Jett Stone: Forget face-lifts and fake knees. Scientists have seen the fountain of youth --- and it's broccoli
The Kosher Gourmet by Chef Mario Batali: The famed chef's vegetable dish that tastes true to the season: FAVAS AND SUGAR SNAP PEAS WITH POTATOES AND TARRAGON
May 10, 2012
Sergei L. Loiko: Putin sends warning to U.S., NATO in Victory Day speech at Red Square
Mary Rourke: How being a 'mentch' got Vidal Sasoon his start and fighting in Israel's War of Independence provided him with confidence and a strong sense of his own identity
Jeff Bertolucci: Get Home Phone Service for Less Than $10 a Month
The Kosher Gourmet by Betty Rosbottom: Gleaming with its golden, crimson, and snowy white hues, this silken smooth and creamy STRAWBERRY ORANGE TRIFLE looks impressive, but is easy to prepare
May 9, 2012
Sharon Palmer, R.D. How you can reduce your risk -- or delay -- chronic diseases associated with aging
|
| |
Jewish World Review
Study: How to Significantly Reduce Mortality from Certain Cancers Simply
By
Thomas H. Maugh II
Study released yesterday by British researchers documents unknown effects of taking regular dosages of commonly found chewable tablets
http://www.JewishWorldReview.com | (MCT)
A daily dose of baby aspirin may reduce mortality from a range of common cancers by an average of 21 percent, and the reduction persisted for at least 20 years, British researchers reported Monday.
Deadly cases of stomach, colorectal and esophageal cancers all declined among people who took low-dose aspirin for 10 to 20 years, according to a study published online in the journal Lancet. The chewable tablets also were linked to a reduced risk of death from adenocarcinoma and from lung cancer in nonsmokers.
The results were based on an analysis of more than 10,000 people who participated in seven clinical trials designed to test whether baby aspirin could reduce the risk of heart disease.
"We already had strong evidence that low-dose aspirin could reduce deaths from colorectal cancer by as much as a third, but this provides important new evidence that long-term aspirin use can provide protection against a variety of other cancers," said epidemiologist Eric Jacobs of the American Cancer Society. However, he added, "it would be premature at this point to recommend that people start using aspirin specifically to prevent cancer."
For the millions of people who are currently taking low doses of aspirin to protect against cardiovascular disease, "the findings suggest that they should have some additional benefit for cancer," said Dr. Lori Minasian, who is in charge of large cancer prevention trials at the National Cancer Institute.
Most of the studies examined by the British researchers involved primarily men, but the team said that the fundamental mechanisms involved probably hold equally for women. However, they added, there were not enough women involved in the studies to determine if daily aspirin could affect mortality from breast, ovarian or endometrial cancer.
A variety of studies in animals — and even in plants — show that salicylate, the active ingredient in aspirin, can suppress tumors. Observational data in the 1970s suggested that aspirin could suppress tumors in humans, but alternative explanations were offered and experts demanded randomized clinical trials.
In October, Dr. Peter M. Rothwell of the University of Oxford and his colleagues reported on an analysis of four clinical trials comparing a daily dose of 75 milligrams of aspirin to a placebo in the prevention of strokes. They found that those who received the aspirin reduced their risk of developing colon cancer by 24 percent and their risk of dying from the disease by 35 percent.
| FREE SUBSCRIPTION TO INFLUENTIAL NEWSLETTER | | Every weekday NewsAndOpinion.com publishes what many in the media and Washington consider "must-reading". HUNDREDS of columnists and cartoonists regularly appear. Sign up for the daily update. It's free. Just click here. | |
(A dose of European baby aspirin is typically 75 mg; in the United States it is 81 mg. A typical full-strength aspirin tablet is 300 mg.)
In the new study, Rothwell and colleagues started with eight clinical trials involving 25,570 people. They found that during the period of the clinical trials, which typically lasted for about four years, the risk of death from cancer declined by about 21 percent among those who were in the aspirin group.
Digging further, the researchers realized that nearly half of the subjects had been tracked for two decades — long after their trials had ended. The researchers "spent several years looking through dusty archives" to track their fates and quantify the long-term benefits of aspirin for cancer prevention, Rothwell said in a news conference.
Over a 10-year period, baby aspirin was linked to a 32 percent reduction in the risk of lung cancers in nonsmokers and a 30 percent drop in the risk of death from adenocarcinoma, the study found. Longer term, aspirin was associated with a 64 percent decrease in fatal cases of esophageal cancer, a 58 percent drop in fatal cases of stomach cancer and a 49 percent reduction in the risk of death from colorectal cancer, the study found.
Aspirin was not found to influence the risk of death from pancreatic, prostate, bladder, kidney, brain or blood cancers, according to the Lancet report. Larger doses of aspirin, smoking and gender had no effect on the results.
Rothwell noted that most of the subjects stopped taking aspirin at the end of the study — or, alternatively, many in the control group began taking it — potentially confusing the results.
"It's likely that if people had carried on taking aspirin," the benefit would have been greater, he said. "The benefit increased quite steeply with the length of time people were on it."
Researchers are not quite sure how the aspirin works. In the test tube, when cells divide, there is a chance the DNA in the daughter cells will be faulty. Healthy cells will recognize those defects and either repair them or cause the defective cells to self-destruct, said Dr. Tom W. Meade of the University of London, a co-author of the paper.
"Both mechanisms are enhanced by aspirin," he said.
The biggest potential risk of aspirin is gastrointestinal bleeding. Rothwell noted that the normal risk of GI bleeding is about one in every 2,000 to 3,000 people per year, and aspirin increases that by about 60 percent. "So the increased risk of bleeding is about 1 in 1,000 per year, while the decreased risk of cancer is 2, 3 or 4 per 1,000 per year," he said.
Interested in a private Judaic studies instructor for free? Let us know by clicking here.
Every weekday JewishWorldReview.com publishes inspirational material. Sign up for the daily JWR update. It's free. Just click here.
We want your comments! Please let us know what you think by clicking here.
if (strpos(, "printer_friendly") === 0)
{}
else {
=<<
© 2010, Los Angeles Times Distributed by McClatchy-Tribune Information Services.
|